AR118407A1 - MULTIVALENT VACCINE COMPOSITION - Google Patents
MULTIVALENT VACCINE COMPOSITIONInfo
- Publication number
- AR118407A1 AR118407A1 ARP190100353A ARP190100353A AR118407A1 AR 118407 A1 AR118407 A1 AR 118407A1 AR P190100353 A ARP190100353 A AR P190100353A AR P190100353 A ARP190100353 A AR P190100353A AR 118407 A1 AR118407 A1 AR 118407A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- ipv
- aluminum hydroxide
- rotavirus
- antigens
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 9
- 102000036639 antigens Human genes 0.000 abstract 9
- 108091007433 antigens Proteins 0.000 abstract 9
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 3
- 241000702670 Rotavirus Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000005702 Pertussis Diseases 0.000 abstract 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 2
- 229940001442 combination vaccine Drugs 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000005847 immunogenicity Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000588832 Bordetella pertussis Species 0.000 abstract 1
- 241000193449 Clostridium tetani Species 0.000 abstract 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 abstract 1
- 101001120172 Crotalus durissus cumanensis Basic phospholipase A2 9 Proteins 0.000 abstract 1
- 241000991587 Enterovirus C Species 0.000 abstract 1
- 241000606768 Haemophilus influenzae Species 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241000617996 Human rotavirus Species 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 1
- 238000005227 gel permeation chromatography Methods 0.000 abstract 1
- 229940047650 haemophilus influenzae Drugs 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a una vacuna o vacunas de combinación inmunogénica estables que comprenden una mezcla de antígenos para la prevención y profilaxis de infecciones causadas por el rotavirus, el virus de la poliomielitis, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis y el virus de la Hepatitis B. La presente proporciona en particular una vacuna de combinación multivalente que comprende: i) antígenos de IPV Salk o IPV Sabin (IPV) en dosis significativamente reducida, preparados mediante la utilización de métodos mejorados de inactivación de formaldehído y adsorción de hidróxido de aluminio, que dan como resultado la recuperación máxima del antígeno D y ii) antígeno(s) de rotavirus inactivado por calor e inyectable obtenido de cepas de rotavirus (CDC-9) que proporcionan una amplia inmunidad de protección cruzada entre las cepas de rotavirus humano, iii) conjugado de PRP de Hib-proteína transportadora que tiene estabilidad e inmunogenicidad mejoradas en donde dicho conjugado de PRP Hib-proteína transportadora es inicialmente preparado usando un nuevo proceso de conjugación y posteriormente se mezcla a baja temperatura en presencia de un estabilizador para minimizar la liberación de PRP libre, iv) antígeno de pertussis de células completas con inmunogenicidad y estabilidad mejoradas obtenidas mediante la adición de antígeno de pertussis de células enteras en una etapa posterior en una mezcla, minimizando así la degradación basada en hidrólisis, v) fracciones homogéneas de toxoide de difteria y toxoide tetánico obtenidos mediante la eliminación de agregados no deseados por el uso de cromatografía por permeación en gel. También se describe el proceso para producir estas composiciones de vacunas inmunogénicas estables mediante las etapas de i) adsorber individualmente IPV en dosis reducida, antígenos de IPV en el hidróxido de aluminio, manteniendo el otro antígeno(s) no absorbido o adsorbido en fosfato de aluminio, hidróxido de aluminio, en una combinación de hidróxido de aluminio y fosfato de aluminio y ii) utilizar un orden particular de adición de antígenos durante la mezcla.This refers to a stable immunogenic combination vaccine or vaccines comprising a mixture of antigens for the prevention and prophylaxis of infections caused by rotavirus, polio virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and the Hepatitis B virus. The present provides in particular a multivalent combination vaccine comprising: i) IPV Salk or IPV Sabin (IPV) antigens in significantly reduced doses, prepared using improved formaldehyde inactivation and adsorption methods. aluminum hydroxide, resulting in maximum recovery of D antigen and ii) injectable heat-inactivated rotavirus antigen (s) derived from rotavirus strains (CDC-9) that provide broad cross-protective immunity between strains of human rotavirus, iii) Hib PRP-carrier protein conjugate having stability and immunogenicity improved quality wherein said PRP Hib-carrier protein conjugate is initially prepared using a new conjugation process and subsequently mixed at low temperature in the presence of a stabilizer to minimize the release of free PRP, iv) whole cell pertussis antigen with improved immunogenicity and stability obtained by adding whole cell pertussis antigen at a later stage in a mixture, thus minimizing degradation based on hydrolysis, v) homogeneous diphtheria toxoid and tetanus toxoid fractions obtained by removing unwanted aggregates by the use of gel permeation chromatography. Also described is the process to produce these stable immunogenic vaccine compositions by the steps of i) individually adsorbing IPV in reduced dose, IPV antigens on aluminum hydroxide, keeping the other antigen (s) unabsorbed or adsorbed on aluminum phosphate. , aluminum hydroxide, in a combination of aluminum hydroxide and aluminum phosphate and ii) using a particular order of antigen addition during mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP190100353A AR118407A1 (en) | 2019-02-13 | 2019-02-13 | MULTIVALENT VACCINE COMPOSITION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP190100353A AR118407A1 (en) | 2019-02-13 | 2019-02-13 | MULTIVALENT VACCINE COMPOSITION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118407A1 true AR118407A1 (en) | 2021-10-06 |
Family
ID=78803795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100353A AR118407A1 (en) | 2019-02-13 | 2019-02-13 | MULTIVALENT VACCINE COMPOSITION |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR118407A1 (en) |
-
2019
- 2019-02-13 AR ARP190100353A patent/AR118407A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5135220B2 (en) | Multiple vaccinations including serogroup C meningococcus | |
| MX2019001780A (en) | NEW MULTIVALENT VACCINE COMPOSITION. | |
| JOP20180069B1 (en) | Immunogenic formula with improved stability, enhanced immunogenicity and reduced reactivity, and process for its preparation | |
| PE20100366A1 (en) | NOVEL COMPOSITIONS OF VACCINE WITH CELLULAR WHOOUS COUGH AS WELL AS THE METHOD FOR ITS ELABORATION | |
| AU2021269395B2 (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
| SI9720050B (en) | Multivalent dtp-polio vaccines | |
| BRPI0810778A2 (en) | kit, combined vaccine, and methods of decreasing crm neighborhood interference over a sensitive antigen in a primary immunization schedule of a vaccine, and decreasing neighborhood interference over a sensitive antigen, and use of saccharide conjugates | |
| AR092896A1 (en) | IMMUNOGENIC COMPOSITIONS | |
| RU2013136397A (en) | COMBINED SEVIVALENT VACCINE | |
| PE20211648A1 (en) | COMPOSITION OF COMBINED VACCINE INCLUDING REDUCED DOSES OF INACTIVATED POLIO VIRUS AND METHOD OF PREPARING IT | |
| AR118407A1 (en) | MULTIVALENT VACCINE COMPOSITION | |
| RU2015111987A (en) | Unstitched acellular pertussis antigens for use in combination vaccines | |
| RU2014147491A (en) | ANTIGENS AND ANTIGENIC COMPOSITIONS | |
| AR067471A1 (en) | A COMPONENT OF ANTI-PERTUSSIS VACCINE AND SIMPLIFIED PROCEDURE TO OBTAIN PERTACTIN (PRN) FROM BORDETELLA PERTUSSIS | |
| ES2224252T3 (en) | VACCINE COMPOSITION THAT INCLUDES FRAGMENTS OF THE BORDETELLA PERTUSSIS EXTERNAL MEMBRANE PROTEIN. | |
| BR112019003419B1 (en) | Combined Vaccine and Manufacturing Process of a Combined Vaccine | |
| OA21991A (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof. | |
| Al-Jadiry | Childhood Immunization | |
| AR097217A1 (en) | IMMUNOGEN COMBINATION COMPOSITIONS |